new YORK (Reuters Health) – long-term use (over
of 10 years) of oestrogen-only therapy is associated with
an increase in the risk of developing breast cancer, according to
it reported a team during the annual meeting of the Association
American for cancer research (AACR, by its
acronym in English), held Chicago.
“Was something that we expected to see,” said author
main, Dr. Wendy y. Chen, of the Brigham Hospital and the
Women, and of the Dana-Farber Institute of Oncology in Boston.
“Has been shown that patients should not receive
“
hormone therapy with estrogen more progesterone in a manner
long. “Now show that they should also take care
with prolonged use of oestrogen-only therapy”, stated.
Risk was linear: to oldest with therapy of
estrogen, increased risk.
“In previous studies, the authors had only evaluated the
“
risks associated with less than 10 years of use of the therapy
hormone. “We wanted to know the effects using one more
prolonged”, added the author.
Chen team assessed study information on the
Health of nurses, which continued to 121.700
nurses certified between 1980 and 2008, who in 1976 had
between 30 and 55 years. Every two years, the participants
responded to different questionnaires.
New analysis included only participants
postmenopausal.
And the team noted that the risk of developing cancer
breast was 88 percent higher in the treated women
with estrogen more progesterone for 10 to 14.9 years than in the
women who had not used that combination. But that
risk of duplicated in participants treated with estrogen
more progesterone for 15 to 19.9 years.
Women only treated with estrogen had a 22 by
% higher risk of developing breast cancer if they had
only used in treatment between 10 and 43 per cent and 14.9 years
more risk if they had used them between 15-19.9 years
compared with the group that had not used the monotherapy
hormonal.
The team assessed a subgroup that information also
it had met the criteria for the inclusion of the randomized trial
known as initiative of women’s health, in which
involved over 50 post-menopausal women.
There, the risk of developing breast cancer declined
slightly in the group treated with oestrogen-only for less
of 10 years, while the risk increased by 30 percent in
women treated with the same therapy during 15 to 19.9
years.
Although the incidence of breast cancer has increased in the
estrogen users more progesterone or estrogen alone,
equipment not recorded an increase in fatal tumors.
Commenting on these results, Dr. Jo Freudenheim, of
the University of Buffalo, in New York, highlighted the
limitations of the observational studies as the Chen.
“There is always the possibility of the emergence of factors
“
confundentes. do with how often women were one
?do
mammography? how many times were the doctor? what kind of access
?do
to health services had? had medical coverage?
Do did exercise? what ate? “All of these factors would be
correlated with the use of hormone therapy”, stated.
And concluded: “There are many unanswered questions.” “Take
estrogen alone for 15 to 20 years is a therapy much more
prolonged which indicated it to many women and could
be that these patients have characteristics somewhat
distinctive”.
